Advanced Imaging for the Early Diagnosis of Local Recurrence Prostate Cancer After Radical Prostatectomy

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2014 Apr 24

PMID 24757679

Citations 12

Authors

Valeria Panebianco

Flavio Barchetti

Daniela Musio

Francesca De Felice

Camilla Proietti

Elena Lucia Indino

Valentina Megna

Orazio Schillaci

Carlo Catalano

Vincenzo Tombolini

Affiliations

Soon will be listed here.

Abstract

Currently the diagnosis of local recurrence of prostate cancer (PCa) after radical prostatectomy (RT) is based on the onset of biochemical failure which is defined by two consecutive values of prostate-specific antigen (PSA) higher than 0.2 ng/mL. The aim of this paper was to review the current roles of advanced imaging in the detection of locoregional recurrence. A nonsystematic literature search using the Medline and Cochrane Library databases was performed up to November 2013. Bibliographies of retrieved and review articles were also examined. Only those articles reporting complete data with clinical relevance for the present review were selected. This review article is divided into two major parts: the first one considers the role of PET/CT in the restaging of PCa after RP; the second part is intended to provide the impact of multiparametric-MRI (mp-MRI) in the depiction of locoregional recurrence. Published data indicate an emerging role for mp-MRI in the depiction of locoregional recurrence, while the performance of PET/CT still remains unclear. Moreover Mp-MRI, thanks to functional techniques, allows to distinguish between residual glandular healthy tissue, scar/fibrotic tissue, granulation tissue, and tumour recurrence and it may also be able to assess the aggressiveness of nodule recurrence.

Citing Articles

Systemic Therapy for Metastatic Hormone-Sensitive Prostate Cancer: A Randomized Controlled Trial-Based Network Meta-Analysis.

Kang Z, Li W, Yu Y, Yang J J Oncol. 2024; 2022:7711555.

PMID: 39280893 PMC: 11401690. DOI: 10.1155/2022/7711555.

Recurrent prostate cancer: combined role for MRI and PSMA-PET in Ga-PSMA-11 PET/MRI.

Jannusch K, Bruckmann N, Morawitz J, Boschheidgen M, Quick H, Herrmann K Eur Radiol. 2023; 34(7):4789-4800.

PMID: 38038758 PMC: 11213774. DOI: 10.1007/s00330-023-10442-4.

Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline.

Cassell A, Yunusa B, Jalloh M, Ndoye M, Mbodji M, Diallo A J Oncol. 2019; 2019:1785428.

PMID: 31885569 PMC: 6915139. DOI: 10.1155/2019/1785428.

Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer.

Schillaci O, Scimeca M, Toschi N, Bonfiglio R, Urbano N, Bonanno E Contrast Media Mol Imaging. 2019; 2019:9429761.

PMID: 31354394 PMC: 6636452. DOI: 10.1155/2019/9429761.

Discrimination of local recurrence after radical prostatectomy: value of diffusion-weighted magnetic resonance imaging.

Kwon T, Kim J, Lee C, Jung J, Ahn H, Kim C Prostate Int. 2018; 6(1):12-17.

PMID: 29556484 PMC: 5857183. DOI: 10.1016/j.prnil.2017.05.002.

References

Scher B, Seitz M, Albinger W, Tiling R, Scherr M, Becker H . Value of 11C-choline PET and PET/CT in patients with suspected prostate cancer. Eur J Nucl Med Mol Imaging. 2006; 34(1):45-53. DOI: 10.1007/s00259-006-0190-7. View

Wo J, Chen M, Nguyen P, Renshaw A, Loffredo M, Kantoff P . Evaluating the combined effect of comorbidity and prostate-specific antigen kinetics on the risk of death in men after prostate-specific antigen recurrence. J Clin Oncol. 2009; 27(35):6000-5. PMC: 7057277. DOI: 10.1200/JCO.2009.23.6067. View

Vargas H, Wassberg C, Akin O, Hricak H . MR imaging of treated prostate cancer. Radiology. 2011; 262(1):26-42. PMC: 6940010. DOI: 10.1148/radiol.11101996. View

Morgan V, Riches S, Giles S, Dearnaley D, deSouza N . Diffusion-weighted MRI for locally recurrent prostate cancer after external beam radiotherapy. AJR Am J Roentgenol. 2012; 198(3):596-602. DOI: 10.2214/AJR.11.7162. View

Picchio M, Crivellaro C, Giovacchini G, Gianolli L, Messa C . PET-CT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging. 2009; 53(2):245-68. View

Casciani E, Polettini E, Carmenini E, Floriani I, Masselli G, Bertini L . Endorectal and dynamic contrast-enhanced MRI for detection of local recurrence after radical prostatectomy. AJR Am J Roentgenol. 2008; 190(5):1187-92. DOI: 10.2214/AJR.07.3032. View

Winter A, Uphoff J, Henke R, Wawroschek F . First results of [11C]choline PET/CT-guided secondary lymph node surgery in patients with PSA failure and single lymph node recurrence after radical retropubic prostatectomy. Urol Int. 2010; 84(4):418-23. DOI: 10.1159/000296298. View

Castellucci P, Fuccio C, Rubello D, Schiavina R, Santi I, Nanni C . Is there a role for ¹¹C-choline PET/CT in the early detection of metastatic disease in surgically treated prostate cancer patients with a mild PSA increase <1.5 ng/ml?. Eur J Nucl Med Mol Imaging. 2010; 38(1):55-63. DOI: 10.1007/s00259-010-1604-0. View

Garcia J, Soler M, Blanch M, Ramirez I, Riera E, Lozano P . [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer]. Rev Esp Med Nucl. 2009; 28(3):95-100. View

10.

Sciarra A, Panebianco V, Salciccia S, Osimani M, Lisi D, Ciccariello M . Role of dynamic contrast-enhanced magnetic resonance (MR) imaging and proton MR spectroscopic imaging in the detection of local recurrence after radical prostatectomy for prostate cancer. Eur Urol. 2008; 54(3):589-600. DOI: 10.1016/j.eururo.2007.12.034. View

11.

Fuccio C, Rubello D, Castellucci P, Marzola M, Fanti S . Choline PET/CT for prostate cancer: main clinical applications. Eur J Radiol. 2010; 80(2):e50-6. DOI: 10.1016/j.ejrad.2010.07.023. View

12.

Somford D, Futterer J, Hambrock T, Barentsz J . Diffusion and perfusion MR imaging of the prostate. Magn Reson Imaging Clin N Am. 2008; 16(4):685-95, ix. DOI: 10.1016/j.mric.2008.07.002. View

13.

Calabria F, Chiaravalloti A, Tavolozza M, Ragano-Caracciolo C, Schillaci O . Evaluation of extraprostatic disease in the staging of prostate cancer by F-18 choline PET/CT: can PSA and PSA density help in patient selection?. Nucl Med Commun. 2013; 34(8):733-40. DOI: 10.1097/MNM.0b013e3283620d5e. View

14.

Fricke E, Machtens S, Hofmann M, van den Hoff J, Bergh S, Brunkhorst T . Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients. Eur J Nucl Med Mol Imaging. 2003; 30(4):607-11. DOI: 10.1007/s00259-002-1104-y. View

15.

Grossfeld G, Stier D, Flanders S, Henning J, SCHONFELD W, Warolin K . Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol. 1998; 160(4):1398-404. View

16.

Schwarzenbock S, Kurth J, Gocke C, Kuhnt T, Hildebrandt G, Krause B . Role of choline PET/CT in guiding target volume delineation for irradiation of prostate cancer. Eur J Nucl Med Mol Imaging. 2013; 40 Suppl 1:S28-35. DOI: 10.1007/s00259-013-2404-0. View

17.

Picchio M, Messa C, Landoni C, Gianolli L, Sironi S, Brioschi M . Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol. 2003; 169(4):1337-40. DOI: 10.1097/01.ju.0000056901.95996.43. View

18.

Sella T, Schwartz L, Swindle P, Onyebuchi C, Scardino P, Scher H . Suspected local recurrence after radical prostatectomy: endorectal coil MR imaging. Radiology. 2004; 231(2):379-85. DOI: 10.1148/radiol.2312030011. View

19.

Stephenson A, Scardino P, Kattan M, Pisansky T, Slawin K, Klein E . Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007; 25(15):2035-41. PMC: 2670394. DOI: 10.1200/JCO.2006.08.9607. View

20.

Giovacchini G, Picchio M, Briganti A, Cozzarini C, Scattoni V, Salonia A . [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. J Urol. 2010; 184(3):938-43. DOI: 10.1016/j.juro.2010.04.084. View